Abiomed (ABMD) Misses Q2 EPS by 4c; Maintains Revenue Outlook
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
EPS Growth %: -100.0%
Financial Fact:
Selling, general and administrative: 53.09M
Today's EPS Names:
WF, CWBC, GLTO, More
EPS Growth %: -100.0%
Financial Fact:
Selling, general and administrative: 53.09M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Abiomed (NASDAQ: ABMD) reported Q2 EPS of $0.20, $0.04 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Abiomed maintains FY2017 revenue of $435-445 million, versus the consensus of $446.33 million.
For earnings history and earnings-related data on Abiomed (ABMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Portland General Electric (POR) Tops Q1 EPS by 6c
- Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
